OBJECTIVE:Carvedilol is a nonselective beta- and alpha(1)-receptor antagonist with additional antioxidant properties in vitro. In this study, we assessed the antioxidative potential of carvedilol in cell culture and in antihypertensive doses in healthy men. METHODS: In vitro, human cultured endothelial cells were treated with native low-density lipoprotein (LDL), oxidized LDL or tumor necrosis factor (TNF)alpha in the absence and in the presence of carvedilol (40 micro M); 8-iso-prostaglandin (PG)F(2alpha), as parameter of oxidative stress, was determined in the supernatants. In a double-blind, randomized, cross-over study, 17 healthy men received 25 mg carvedilol b.i.d., 100 mg metoprolol b.i.d. or placebo for 6 days. After each treatment, systemic oxidative stress was assessed by measuring urinary excretion of 8-iso-PGF(2alpha) and 2,3-dinor-5,6-dihydro-8-iso-PGF(2alpha), and the plasma concentration of 3-nitrotyrosine by means of gas chromatography-tandem mass spectrometry. In addition, thiobarbituric acid-reactive substances (TBARS) in plasma were assessed using spectrophotometry. RESULTS: Native LDL and oxidized LDL induced 8-iso-PGF(2alpha) production in endothelial cells. Carvedilol significantly reduced this effect (e.g., for oxidized LDL: 2.66+/-0.22 pg vs 1.46+/-0.14 pg 8-iso-PGF(2alpha) per micro g protein, P<0.05). In healthy volunteers, carvedilol and metoprolol markedly decreased blood pressure and heart rate, but had no statistically significant effect on any indicator of oxidative stress measured. Remarkably, a trend toward reduction of urinary isoprostanes and 3-nitrotyrosine in plasma by both active treatments was observed, suggesting a non-specific antioxidative effect by beta blockade. CONCLUSIONS: In vitro, the antioxidative potential of carvedilol was confirmed. In healthy men, antihypertensive doses of carvedilol exert no specific inhibition of oxidative stress.
RCT Entities:
OBJECTIVE:Carvedilol is a nonselective beta- and alpha(1)-receptor antagonist with additional antioxidant properties in vitro. In this study, we assessed the antioxidative potential of carvedilol in cell culture and in antihypertensive doses in healthy men. METHODS: In vitro, human cultured endothelial cells were treated with native low-density lipoprotein (LDL), oxidized LDL or tumor necrosis factor (TNF)alpha in the absence and in the presence of carvedilol (40 micro M); 8-iso-prostaglandin (PG)F(2alpha), as parameter of oxidative stress, was determined in the supernatants. In a double-blind, randomized, cross-over study, 17 healthy men received 25 mg carvedilol b.i.d., 100 mg metoprolol b.i.d. or placebo for 6 days. After each treatment, systemic oxidative stress was assessed by measuring urinary excretion of 8-iso-PGF(2alpha) and 2,3-dinor-5,6-dihydro-8-iso-PGF(2alpha), and the plasma concentration of 3-nitrotyrosine by means of gas chromatography-tandem mass spectrometry. In addition, thiobarbituric acid-reactive substances (TBARS) in plasma were assessed using spectrophotometry. RESULTS: Native LDL and oxidized LDL induced 8-iso-PGF(2alpha) production in endothelial cells. Carvedilol significantly reduced this effect (e.g., for oxidized LDL: 2.66+/-0.22 pg vs 1.46+/-0.14 pg 8-iso-PGF(2alpha) per micro g protein, P<0.05). In healthy volunteers, carvedilol and metoprolol markedly decreased blood pressure and heart rate, but had no statistically significant effect on any indicator of oxidative stress measured. Remarkably, a trend toward reduction of urinary isoprostanes and 3-nitrotyrosine in plasma by both active treatments was observed, suggesting a non-specific antioxidative effect by beta blockade. CONCLUSIONS: In vitro, the antioxidative potential of carvedilol was confirmed. In healthy men, antihypertensive doses of carvedilol exert no specific inhibition of oxidative stress.
Authors: P W Serruys; D P Foley; B Höfling; J Puel; H D Glogar; R Seabra-Gomes; J Goicolea; P Coste; W Rutsch; H Katus; H Bonnier; W Wijns; A Betriu; U Hauf-Zachariou; E M van Swijndregt; R Melkert; R Simon Journal: Circulation Date: 2000-04-04 Impact factor: 29.690
Authors: L Rössig; J Haendeler; Z Mallat; B Hugel; J M Freyssinet; A Tedgui; S Dimmeler; A M Zeiher Journal: J Am Coll Cardiol Date: 2000-12 Impact factor: 24.094
Authors: Dimitrios Tsikas; Edzard Schwedhelm; Maria Theresia Suchy; Jonas Niemann; Frank Mathias Gutzki; Veit J Erpenbeck; Jens M Hohlfeld; Andrzej Surdacki; Jürgen C Frölich Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2003-09-05 Impact factor: 3.205
Authors: Thomas C Malig; Mitchell R Ashkin; Austin L Burman; Manuel Barday; Belinda J M Heyne; Thomas G Back Journal: Medchemcomm Date: 2017-01-30 Impact factor: 3.597
Authors: Aaron S Kelly; J Michael Gonzalez-Campoy; Kyle D Rudser; Harold Katz; Andrea M Metzig; Melissa Thalin; Alan J Bank Journal: J Clin Hypertens (Greenwich) Date: 2011-12-19 Impact factor: 3.738